Society of Gynecologic Oncology Publications
- Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.
- In December 2018, the Policy, Quality, and Outcomes Taskforce of the SGO convened a daylong seminar including experts in the field of PROs to further SGO's vision of integrating PROMs into routine clinical practice as a component of patient-centric care. Recognizing our role in managing cancer patients across the entire continuum of surgical and medical care, we believe gynecologic oncologists are uniquely positioned to make important contributions to this field and influence the delivery of care in the wider discipline of oncology.
- Health-related quality of life (HRQoL) has been increasingly recognized as a critical metric to ensure delivery of high quality, patient-centered cancer care. HRQoL can be measured in several ways, but often involves collecting patient reported outcomes (PROs). PROs collected on validated questionnaires are known as patient reported outcome measures (PROMs).
- The COVID-19 pandemic has challenged our ability to provide timely surgical care for our patients. In response, the U.S. Surgeon General, the American College of Srugeons, and other surgical professional societies recommended postponing elective surgical procedures and proceeding cautiously with cancer procedures that may require significant hospital resources and expose vulnerable patients to the virus. These challenges have particularly distressing for women with a gynecologic cancer diagnosis and their providers.
- The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them at high risk for COVID 19 morbidity or mortality. Highly immunosuppressive chemotherapy regimens and possible exposure to COVID-19 during treatment may put patients at additional risk. The Society of Gynecologic Oncology convened an expert panel to address recommendations for best practices during this crisis to minimize risk to patients from deviations in cancer care and from COVID-19 morbidity.